AKT1 and leukemia: Higher doses might be required in leukemia cells to inhibit mTOR binding to RICTOR, but we did not detect any decrease in AKT pSer473 levels following treatment of Jurkat cells with up to 50 μM JR-AB2-011 (Fig. 3b).